Amgen Presentations & Investor Relations material
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to and thank you for your assistance.
amgen.comAmgen presentations
AMGEN Investor Presentation 2020
Amgen
American Academy of Dermatology Investor Call
Amgen
Q1 16 Earnings Call
Amgen
AMG 160 Data at Esmo Virtual Congress 2020
Amgen
Q117 Earnings Call
Amgen
AMG 133 Program Update
Amgen
Q4 ’23 Earnings Call
Amgen
Amgen at Asco20 Virtual Scientific Program
Amgen
Tezepelumab: a Differentiated, First-in-class Investigational Therapy For a Broad Population With Severe Uncontrolled Asthma
Amgen
Amgen Q2 ’15 Earnings Call
Amgen
2021 Annual Meeting of Stockholders
Amgen
Amgen to Acquire Horizon Therapeutics
Amgen
Q1 ’15 Earnings Call
Amgen
Biosimilars
Amgen
Investor Presentation
Amgen
Repatha: Steps to Improve Affordability and Access for Patients with Cardiovascular Disease
Amgen
Amgen Q3 ’15 Earnings Call
Amgen
Amgen Sotorasib Data at Esmo Virtual Congress 2020
Amgen
AMGEN Q4 ’15 Earnings Call
Amgen
Q4 ’17 EARNINGS CALL
Amgen
Amg 510 Update From Esmo 2019
Amgen
Q3 ’16 Earnings Call
Amgen
Q2 ’16 Earnings Call
Amgen
Amgen Q1 ’23 Earnings Call
Amgen
2014 Business Review
Amgen
Q4 ’18 Earnings Call
Amgen
42 Nd Annual J.P. Morgan Healthcare Conference
Amgen
Amgen Q2 14 Earnings Call
Amgen
Investor Presentation
Amgen
Q3 19 Earnings Call
Amgen
Amgen 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Amgen
Q1 19 Earnings Call
Amgen
36th Annual J.P. Morgan Healthcare Conference
Amgen
KHK4083 Collaboration with Kyowa Kirin Lumakras™ (Sotorasib) Approval
Amgen
Hematology / Oncology Update Esmo 2023
Amgen
Q1 21 Earnings Call
Amgen
Categories
Finance PresentationsTechnology PresentationsBanking PresentationsInformation Technology PresentationsOil and Energy PresentationsInternet PresentationsMining and Metals PresentationsCommunications PresentationsReal Estate PresentationsBiotechnology PresentationsAutomotive PresentationsMedical PresentationsRetail PresentationsEnergy Presentations